Wang Hai-long, Wang Shao-shan, Song Wen-hui, Pan Yi, Yu Hai-peng, Si Tong-guo, Liu Yong, Cui Xiao-nan, Guo Zhi
Department of Interventional Treatment, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer Laboratory of Cancer Prevention and Therapy, Tianjin, China; Department of Oncology, Dagang Hospital of Binhai New Area, Tianjin, China.
Department of Oncology, Dagang Hospital of Binhai New Area, Tianjin, China.
PLoS One. 2015 May 15;10(5):e0125924. doi: 10.1371/journal.pone.0125924. eCollection 2015.
Prostate-specific membrane antigen (PSMA) has been found in tumor neovasculature endothelial cells (NECs) of non-prostate cancers and may become the most promising target for anti-tumor therapy. To study the value of PSMA as a potential new target for lung cancer treatment, PSMA expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) tissues and its relationship with clinicopathology were investigated in the current study.
Immunohistochemistry was used to detect PSMA expression in a total of 150 lung specimens of patients with lung cancer. The data were analyzed using univariate and multivariate statistical analyses.
The percentages of NSCLC patients who had PSMA (+) tumor cells and PSMA (+) NECs were 54.02% and 85.06%, respectively. The percentage of patients younger than 60 years old who had PSMA (+) tumor cells was 69.05%, which was significantly greater than the percentage of patients aged 60 years or older (40.00%, p<0.05). A significant difference was observed in the percentage of NSCLC patients with PMSA (+) NECs and stage I or II cancer (92.98%) and those patients with stage III or IV cancer (76.77%). In the SCLC tissues, NEC PSMA expression (70.00%) did not differ significantly from NSCLC. SCLC tumor cells and normal lung tissues cells were all negative. There was no significant correlation between the presence of PSMA (+) NECs in SCLC patients and the observed clinicopathological parameters.
PSMA is expressed not only in NECs of NSCLC and SCLC but also in tumor cells of most NSCLC patients. The presence of PSMA (+) tumor cells and PSMA (+) NECs in NSCLC was negatively correlated with age and the clinicopathological stage of the patients, respectively.
在非前列腺癌的肿瘤新生血管内皮细胞（NECs）中发现了前列腺特异性膜抗原（PSMA），其可能成为最有前景的抗肿瘤治疗靶点。为研究PSMA作为肺癌治疗潜在新靶点的价值，本研究调查了非小细胞肺癌（NSCLC）和小细胞肺癌（SCLC）组织中PSMA的表达及其与临床病理特征的关系。
采用免疫组织化学法检测150例肺癌患者肺标本中PSMA的表达。数据采用单因素和多因素统计分析。
NSCLC患者中PSMA（+）肿瘤细胞和PSMA（+）NECs的比例分别为54.02%和85.06%。年龄小于60岁的患者中PSMA（+）肿瘤细胞的比例为69.05%，显著高于60岁及以上患者（40.00%，p<0.05）。NSCLC患者中PMSA（+）NECs且处于Ⅰ期或Ⅱ期癌症的比例（92.98%）与处于Ⅲ期或Ⅳ期癌症的患者（76.77%）之间存在显著差异。在SCLC组织中，NEC PSMA表达（70.00%）与NSCLC无显著差异。SCLC肿瘤细胞和正常肺组织细胞均为阴性。SCLC患者中PSMA（+）NECs的存在与观察到的临床病理参数之间无显著相关性。
PSMA不仅在NSCLC和SCLC的NECs中表达，而且在大多数NSCLC患者的肿瘤细胞中也表达。NSCLC中PSMA（+）肿瘤细胞和PSMA（+）NECs的存在分别与患者年龄和临床病理分期呈负相关。
